# 2025年12月30日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 无肥胖的 COVID-19 患者的二甲双胍治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41460509)
**期刊：** JAMA internal medicine
**PMID：** 41460509
**DOI：** 10.1001/jamainternmed.2025.6793

### 第一部分 原文与翻译

**英文原标题：** Metformin Therapy for Patients With COVID-19 Without Obesity.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究关注二甲双胍在无肥胖 COVID-19 患者中的潜在疗效与安全性，这是对以往主要聚焦肥胖人群研究的补充。研究可能旨在阐明代谢调节药物在不同表型患者中的作用差异。若确有数据支持，其发现将有助于重新审视二甲双胍在感染性疾病中的适应证。然而，缺乏摘要使得研究设计与主要结果尚不明确，未来需结合原文或随机对照试验进一步评估其临床意义。

---

## 2. SIRT2 调控脓毒性休克患者外周血单个核细胞的体外黏附反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41460289)
**期刊：** Shock (Augusta, Ga.)
**PMID：** 41460289
**DOI：** 10.1097/SHK.0000000000002773

### 第一部分 原文与翻译

**英文原标题：** SIRT2 Regulates Ex Vivo PBMC Adhesion in Septic Shock Patients.

> **英文摘要：**
> BACKGROUND: Septic shock (SS) is deadly. Sepsis-immune response transitions from an endotoxin-sensitive, hyper-inflammatory phase to an endotoxin-tolerant hypo-inflammatory phase. In mice, we implicated sirtuin 2 (SIRT2) for prolonged hypo-inflammation using leukocyte adhesion, the earliest in vivo inflammatory response to cytokine, chemokine, and metabolite stimuli. The role of SIRT2 in human sepsis remains unknown. We hypothesized that: 1. Peripheral blood mononuclear cells (PBMCs) adhesion response can be used as a physiological biomarker of hypo-inflammation, and 2. SIRT2 regulates the functions of PBMCs and macrophages during the hypo-inflammatory phase of human sepsis.
> 
> METHODS: We stimulated control and SS-whole blood and PBMCs ± lipopolysaccharide (LPS) and investigated plasma cytokines, PBMC cell adhesion to ICAM-1 coated plates, adhesion molecule CD18 activation, SIRT2 expression, and cytokine response. In adhesion/endotoxin-tolerant PBMCs and THP-1 cells treated ± SIRT2 inhibitor AK-7, we analyzed cell adhesion, CD18 activation, and transmigration ± LPS. In monocyte-derived macrophages (MDMs) from SS vs. controls ± AK-7, we analyzed phagocytosis.
> 
> RESULTS: We found: 1. Muted plasma TNF and IL-1β-response to LPS in SS vs. control (endotoxin-tolerance) 2. Endotoxin-tolerant SS-PBMCs exhibit high SIRT2 expression, and muted adhesion (adhesion-tolerance), CD18 activation, and transmigration with LPS. 3. SIRT2 inhibitor AK-7 reverses endotoxin and adhesion-tolerance in SS-PBMCs via CD18 activation, reverses the defective transmigration of endotoxin-tolerant PBMCs and improves phagocytosis in MDMs from SS patients.
> 
> CONCLUSION: PBMC adhesion, a physiological biomarker, can be used to detect hypo-inflammation. Defective PBMC and macrophage function in septic shock patients occur via high SIRT2 expression. SIRT2 inhibition is a potential therapeutic strategy for treating sepsis-associated hypo-inflammation.

> **中文摘要：**
> 背景：脓毒性休克（SS）具有极高的致死性。脓毒症的免疫反应会从内毒素敏感的高炎症阶段逐渐过渡到内毒素耐受的低炎症阶段。在小鼠模型中，我们发现沉默信息调控蛋白2（SIRT2）参与了延长的低炎症状态，这一过程通过白细胞黏附体现——此为细胞因子、趋化因子及代谢物刺激下体内最早出现的炎症反应。SIRT2在人体脓毒症中的作用尚不清楚。我们假设：（1）外周血单个核细胞（PBMCs）的黏附反应可作为低炎症状态的生理生物标志物；（2）SIRT2在人体脓毒症低炎症阶段调控PBMCs及巨噬细胞的功能。
> 
> 方法：我们分别刺激健康对照者和SS患者的全血及PBMCs（±脂多糖LPS），检测血浆细胞因子水平、PBMC对ICAM-1包被板的黏附、黏附分子CD18的活化、SIRT2表达及细胞因子反应。在黏附/内毒素耐受的PBMCs和THP-1细胞中（±SIRT2抑制剂AK-7处理），分析细胞黏附、CD18活化及（±LPS）穿越迁移能力。在来源于SS患者及对照者的单核细胞衍生巨噬细胞（MDMs）（±AK-7）中，评估吞噬能力。
> 
> 结果：我们发现：（1）与对照组相比，SS患者血浆TNF及IL-1β对LPS的反应减弱（表现为内毒素耐受）；（2）内毒素耐受的SS-PBMCs中SIRT2表达升高，LPS刺激下的黏附（黏附耐受）、CD18活化及迁移能力均减弱；（3）SIRT2抑制剂AK-7可通过促进CD18活化逆转SS-PBMCs的内毒素与黏附耐受，改善内毒素耐受PBMCs迁移缺陷，并提升SS患者MDMs的吞噬功能。
> 
> 结论：PBMC黏附可作为一种检测低炎症状态的生理生物标志物。SS患者中PBMC及巨噬细胞功能障碍是由SIRT2高表达介导的。抑制SIRT2可能成为治疗脓毒症相关低炎症状态的潜在策略。

### 第二部分 AI 大师评价

本研究聚焦SIRT2在脓毒性休克低炎症阶段的免疫调控作用，提出PBMC黏附反应作为低炎症的潜在生理性标志物。通过对患者PBMCs、THP-1细胞及MDMs的功能分析，作者揭示SIRT2高表达与内毒素和黏附耐受密切相关，且SIRT2抑制剂AK-7能逆转这一状态并改善吞噬功能。该研究首次在人类样本中确认SIRT2在败血症免疫抑制阶段的关键作用，具有一定的创新性。其局限性在于样本规模较小且仍需进一步临床验证。

---

## 3. 我们是否达成共识？重症患者家属预后期望的临床医生感知研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41460154)
**期刊：** Critical care medicine
**PMID：** 41460154
**DOI：** 10.1097/CCM.0000000000007004

### 第一部分 原文与翻译

**英文原标题：** Are We on the Same Page? Clinician Perceptions of Family Prognostic Expectations for Critically Ill Patients.

> **英文摘要：**
> OBJECTIVES: To examine how accurately ICU clinicians perceived family-reported prognostic expectations (FPEs) for patients with prolonged mechanical ventilation (PMV).
> 
> DESIGN: A cross-sectional, exploratory design using secondary analysis.
> 
> SETTING: Thirteen ICUs across five hospitals in the United States.
> 
> SUBJECTS: Family members of patients with PMV and ICU clinicians, including physicians and nurses.
> 
> INTERVENTIONS: None.
> 
> MEASUREMENTS AND MAIN RESULTS: Latent profile analysis was used to identify profiles of accuracy in clinician perception of FPE, followed by bivariate analyses and multinomial logistic regression to examine associations between patient, family, and clinician characteristics and profile membership. A total of 554 participants (239 family members, 150 physicians, and 165 nurses) were included. Five distinct latent profiles of accuracy in clinician perception of FPE were identified: 1) clinician underestimation of FPE; 2) clinician overestimation of FPE; 3) accurate perception: low prognosis; 4) accurate perception: moderate prognosis; and 5) accurate perception: high prognosis. Families in profile 1 (clinician underestimation of FPE) were more likely to be spouses/partners of patients and reported higher levels of hope and optimism, whereas those in profile 2 (clinician overestimation of FPE) reported lower levels. Patient characteristics, including age, employment status, admission to medical ICU, and pulmonary-related hospital diagnosis, were statistically significantly associated with the profile membership.
> 
> CONCLUSIONS: Understanding how accurately clinicians perceive FPE is vital to improving shared decision-making and developing goal-concordant care for patients with PMV. Further research examining strategies for clinicians to accurately perceive what families believe about prognosis is needed to identify potential misalignment, initiate timely and empathetic conversations, and build toward shared decision-making and goal-concordant care.

> **中文摘要：**
> 研究目的：探讨重症监护病房（ICU）临床医生对长期机械通气（PMV）患者家属报告的预后期望（FPE）的感知准确性。
> 
> 研究设计：采用横断面、探索性设计，基于二次数据分析。
> 
> 研究场所：美国五家医院的13个ICU。
> 
> 研究对象：PMV患者的家属及ICU临床医生（包括医生和护士）。
> 
> 干预措施：无。
> 
> 测量与主要结果：采用潜在特征分析识别临床医生对FPE感知准确性的潜在类型，并利用双变量分析及多项逻辑回归分析患者、家属和临床医生特征与类型归属之间的关系。共纳入554名参与者（239名家属、150名医生和165名护士）。识别出重症医生感知FPE准确性的五类潜在特征：1）低估家属预期的临床医生；2）高估家属预期的临床医生；3）感知准确：低预后；4）感知准确：中等预后；5）感知准确：高预后。第1类（临床医生低估FPE）的家属更可能是患者的配偶/伴侣，并报告更高水平的希望和乐观，而第2类（临床医生高估FPE）家属报告的希望与乐观水平较低。患者特征（包括年龄、就业状态、入住内科ICU以及肺部相关住院诊断）与类型归属具有统计学显著关联。
> 
> 结论：理解临床医生对家属预后期望的感知准确性对于促进共同决策及制定符合目标的护理方案至关重要。进一步研究应探讨帮助医生准确理解家属预后信念的策略，以识别潜在的不一致，开展及时且具同理心的沟通，并推进共同决策与目标一致的护理。

### 第二部分 AI 大师评价

本研究以多中心ICU为基础，系统评估了临床医生对长期机械通气患者家属预后期望的感知准确性。通过潜在特征分析和多变量统计方法，揭示了五种感知模式及其与家属、患者和临床医生特征的关联。研究结果强调了认知偏差在医患沟通与共同决策中的作用，提示提升临床医生理解家属信念的能力对目标一致性护理具有重要意义。其创新性在于首次量化评估该感知差异，但研究为横断面设计，尚需纵向研究验证因果关系。

---

## 4. 高流量鼻导管治疗期间呼吸努力的监测：膈肌超声有无作用？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41460152)
**期刊：** Critical care medicine
**PMID：** 41460152
**DOI：** 10.1097/CCM.0000000000007012

### 第一部分 原文与翻译

**英文原标题：** Monitoring Respiratory Effort During High-Flow Nasal Cannula Therapy: Any Role for Diaphragmatic Ultrasound?

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究聚焦于高流量鼻导管治疗（HFNC）过程中呼吸努力的客观评估问题，探讨膈肌超声作为一种无创监测手段的潜在价值。尽管摘要缺失，但从标题推测，作者可能评估了膈肌运动参数在患者呼吸功估算中的可行性及临床意义。该主题具有较强的创新性，对重症监护中呼吸支持管理具有潜在指导意义。然而，其研究设计与结果细节尚未披露，需结合原文验证结论的科学性与临床应用性。

---

## 5. 重症监护病房医院获得性肺炎患者中持续输注哌拉西林的药代动力学/药效学目标达成情况研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41460103)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41460103
**DOI：** 10.1128/aac.01760-25

### 第一部分 原文与翻译

**英文原标题：** Pharmacokinetic-pharmacodynamic target attainment with continuous infusion piperacillin in patients admitted to the ICU with hospital-acquired pneumonia.

> **英文摘要：**
> Optimizing β-lactam antibiotic exposure in critically ill patients with hospital-acquired pneumonia (HAP) remains a challenge due to significant pharmacokinetic variability, particularly in the setting of renal dysfunction and replacement therapies. Continuous infusion (CI) of piperacillin/tazobactam aims to improve pharmacodynamic target attainment, though both subtherapeutic and potentially toxic concentrations have been reported in practice. We developed a population pharmacokinetic model of piperacillin using 162 plasma samples from 35 intensive care unit (ICU) patients with HAP, including those receiving continuous renal replacement therapy (CRRT). Piperacillin concentrations were quantified using a validated LC-MS method. A one-compartment model parameterized with renal and non-renal clearance was implemented in Monolix, incorporating creatinine clearance (CrCL), CRRT effluent flow rate, and intermittent hemodialysis as key covariates. Monte Carlo simulations in Simulx evaluated steady-state drug exposures following renal dose-adjusted CI regimens. Simulation showed that renally adjusted lower doses administered via CI (3-9 g/day) achieved target concentrations in 74-82% of patients with CrCL ≤75 mL/min. Higher doses (6-12 g/day) resulted in >20% of patients exceeding 96 mg/L across all renal strata. Among CRRT patients, lower doses provided a 100% probability of maintaining targeted piperacillin concentrations. In patients with supra-normal renal function (i.e., CrCL = 150 mL/min), low-dose CI regimens yielded a 6.1% probability of underexposure, compared to 2.7% with high-dose. CI PIP dosing based on CrCL results in variable exposures among ICU patients. Individualized dosing of PIP may be required to optimize efficacy and minimize toxicity in ICU patients treated with CI dosing.

> **中文摘要：**
> 由于药代动力学变异性显著，尤其是在肾功能障碍及肾脏替代治疗患者中，优化重症医院获得性肺炎（HAP）患者对β-内酰胺类抗生素的暴露仍是一项挑战。持续输注（CI）哌拉西林/他唑巴坦旨在改善药效学目标的达成率，然而在临床实践中既有报告提示亚治疗性浓度，也存在潜在毒性水平的浓度。我们基于35例重症监护病房（ICU）HAP患者（其中包括接受连续肾脏替代治疗〔CRRT〕者）采集的162份血浆样本，建立了哌拉西林的人群药代动力学模型。哌拉西林浓度采用经验证的液相色谱-质谱（LC-MS）方法进行定量。单室模型在 Monolix 软件中实现，参数化包括肾性及非肾性清除率，并引入肌酐清除率（CrCL）、CRRT废液流速及间歇性血液透析作为关键协变量。随后在 Simulx 中进行蒙特卡罗模拟，以评估经肾功能调整剂量的持续输注方案下稳态药物暴露。模拟结果显示，通过CI给药的肾功能调整低剂量（3–9 g/日）方案在CrCL ≤75 mL/min的患者中可在74–82%的情况下达到目标浓度。较高剂量（6–12 g/日）方案则导致所有肾功能亚组中超过20%的患者血药浓度高于96 mg/L。在CRRT患者中，低剂量方案可100%维持目标哌拉西林浓度。对于肾功能超常（如CrCL = 150 mL/min）的患者，低剂量CI方案有6.1%的暴露不足概率，而高剂量则为2.7%。基于CrCL的CI哌拉西林给药在ICU患者中导致暴露差异显著。为优化疗效并减少毒性，ICU患者的CI哌拉西林应进行个体化剂量调整。

### 第二部分 AI 大师评价

该研究通过建立基于ICU医院获得性肺炎患者的哌拉西林群体药代动力学模型，系统评估了持续输注不同肾功能调整剂量的药效学目标达成情况。研究方法严谨，结合LC-MS定量与蒙特卡罗模拟，揭示了持续输注在不同肾功能患者中可能出现的药物暴露差异。结果显示，低剂量在CRRT患者中可充分达标，而高剂量存在潜在毒性风险。该研究为重症患者的个体化β-内酰胺类抗生素治疗提供了数据支持，但样本量有限及模拟假设仍需临床研究进一步验证。

---

## 6. NDM-63：一种来源于临床分离株、位于L3环的新型NDM金属-β-内酰胺酶变体

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41460102)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41460102
**DOI：** 10.1128/aac.01286-25

### 第一部分 原文与翻译

**英文原标题：** NDM-63: a novel NDM metallo-β-lactamase variant in the L3 loop, from a  clinical isolate.

> **英文摘要：**
> NDM-type metallo-β-lactamases (MBLs) are among the most widespread acquired carbapenemases in carbapenem-resistant Enterobacterales. As with other β-lactamases, allelic variability occurs among NDM-type MBLs, with almost 100 variants so far reported, differing by single or multiple amino acid substitutions or insertions, which may have implications for enzymatic activity. In this study, we report on a novel NDM variant, NDM-63, identified in a carbapenem-resistant ST147  from a surveillance rectal swab. Compared to NDM-1, NDM-63 features an original array of changes in the L3 loop, including deletion of phenylalanine at position 70 and two amino acid substitutions (G69S and A72H), due to a four-nucleotide deletion plus a nucleotide insertion in the gene region encoding the L3 loop. When expressed in  under isogenic conditions, NDM-63 conferred a resistance profile overall similar to NDM-1, but exhibiting a lower level of resistance to carbapenems and cefepime, while remaining susceptible to inhibition by taniborbactam. Present findings expand current knowledge on the structural plasticity of NDM-type MBLs and highlight that variability in the L3 loop, which contributes to delimitation of the active site, could also tolerate amino acid deletions without loss of enzymatic activity. A virtually identical  carrying a non-functional  allele entailing only the nucleotide insertion observed in  (which might have played a role in the evolution of ) was also isolated from a bloodstream infection that occurred in the same patient, yielding a misleading result of molecular diagnostic testing due to the lack of enzyme activity despite the presence of the target gene.

> **中文摘要：**
> NDM型金属-β-内酰胺酶（MBLs）是碳青霉烯耐药肠杆菌中最广泛获得的碳青霉烯酶之一。与其他β-内酰胺酶类似，NDM型MBLs之间也存在等位基因变异，目前已报告近百种变体，它们由于单个或多个氨基酸替换或插入而产生差异，这些变化可能影响酶的活性。在本研究中，我们报道了一种新的NDM变体NDM-63，该变体从一例监测性直肠拭子中分离出的碳青霉烯耐药ST147菌株中鉴定得到。与NDM-1相比，NDM-63在L3环中表现出独特的变化，包括位点70的苯丙氨酸缺失以及两个氨基酸替换（G69S和A72H），这些变化源于编码L3环的基因区内出现的一个四核苷酸缺失和一个核苷酸插入。当在同基因背景条件下表达时，NDM-63赋予的耐药谱总体上与NDM-1相似，但对碳青霉烯类和头孢吡肟的耐药水平较低，同时仍对抑制剂taniborbactam敏感。当前发现拓展了我们对NDM型MBLs结构可塑性的认识，并强调了L3环的变异（其参与限定活性位点）可在不丧失酶活性的情况下容忍氨基酸缺失。此外，从同一患者的血流感染样本中还分离出一个几乎相同但携带非功能性等位基因的菌株，该等位基因仅具有前述的核苷酸插入，可能在NDM-63的进化中发挥作用。由于该菌株尽管携带目标基因但缺乏酶活性，因此在分子诊断检测中产生了误导性结果。

### 第二部分 AI 大师评价

该研究通过分子和功能分析鉴定并描述了一种新的NDM金属-β-内酰胺酶变体NDM-63，重点关注其L3环区域的特殊结构变异。实验比较显示，NDM-63与NDM-1的整体耐药谱相似，但耐药水平略低，并且对taniborbactam保持敏感。研究揭示NDM结构的高度可塑性，说明活性位点附近的L3环能够容忍氨基酸缺失而不损失酶功能。该发现加深了对NDM型酶进化机制及耐药性结构基础的理解，但仍需进一步结构与动力学研究验证其功能调节机制。

---

## 7. 在因医院获得性肺炎入住重症监护病房患者中，哌拉西林/他唑巴坦关键阈值目标达成率的研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41460101)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41460101
**DOI：** 10.1128/aac.01766-25

### 第一部分 原文与翻译

**英文原标题：** Critical threshold target attainment rates for tazobactam combined with piperacillin among patients admitted to the ICU with hospital-acquired pneumonia.

> **英文摘要：**
> Optimizing antibiotic exposures in hospital-acquired pneumonia (HAP) is crucial; however, dosing decisions often overlook target levels for the beta-lactamase inhibitor tazobactam (TAZ), and the impact of renal dysfunction and renal replacement therapy on TAZ pharmacokinetics (PK) remains poorly described. We developed a population PK model of TAZ using 162 plasma samples from 35 ICU patients with HAP, including those receiving continuous renal replacement therapy (CRRT). TAZ concentrations were quantified using validated LC-MS/MS methods. A one-compartment model was fit using Monolix, with clearance modeled as a function of creatinine clearance, CRRT effluent flow rate, and intermittent hemodialysis. Monte Carlo simulations assessed the probability of unbound TAZ concentrations exceeding 1, 2, or 4 mg/L for 100% of the interval between 24 and 48 h across intermittent, extended, and continuous infusion (CI) regimens, stratified by renal function and CRRT. TAZ clearance was driven by renal function and CRRT flow rate. All regimens achieved ≥90% probability of target attainment (PTA) at thresholds of 1-2 mg/L. At 4 mg/L, PTA fell below 90% in patients with creatinine clearance ≥150 mL/min for all regimens, with low-dose CI performing the worst. High-dose CI improved PTA at this higher threshold but may increase the risk of piperacillin overexposure. TAZ exposures sufficient for enzymatic beta-lactamase inhibition are generally achieved with standard dosing for lower thresholds but not for more aggressive targets (e.g., high extended-spectrum β-lactamase expression), particularly in patients with preserved or augmented renal function, who may require therapeutic drug monitoring or alternative therapy.

> **中文摘要：**
> 在医院获得性肺炎（HAP）中优化抗生素暴露至关重要；然而，剂量决策往往忽视了对β-内酰胺酶抑制剂他唑巴坦（TAZ）目标水平的考虑，而肾功能障碍及肾脏替代治疗对TAZ药代动力学（PK）的影响仍未得到充分描述。本研究基于来自35例HAP重症监护病房（ICU）患者（其中包括接受连续性肾脏替代治疗[CRRT]的患者）的162份血浆样本，建立了TAZ的群体药代动力学模型。TAZ浓度通过验证的液相色谱-串联质谱（LC-MS/MS）方法定量测定。利用Monolix拟合一室模型，并将清除率设定为肌酐清除率、CRRT废液流速和间歇性血液透析的函数。通过蒙特卡洛模拟，在不同肾功能和CRRT分层条件下，评估间歇输注、延长输注及持续输注（CI）方案中TAZ未结合浓度在24至48小时内100%时间超过1、2或4 mg/L的概率（PTA）。结果显示，TAZ清除主要受肾功能和CRRT流速驱动。所有给药方案在1–2 mg/L阈值时均达到≥90%的目标达成概率（PTA）。在4 mg/L阈值下，对于肌酐清除率≥150 mL/min的患者，所有方案的PTA均低于90%，其中低剂量CI表现最差。高剂量CI可改善该高阈值下的PTA，但可能增加哌拉西林过度暴露的风险。标准剂量在较低目标阈值下通常能获得足以抑制β-内酰胺酶活性的TAZ暴露，但对于更高强度的目标（如高产超广谱β-内酰胺酶的情况）则可能不足，尤其是在肾功能保留或增强的患者中，这类患者或需进行治疗药物监测或考虑替代方案。

### 第二部分 AI 大师评价

本研究针对医院获得性肺炎ICU患者中他唑巴坦 pharmacokinetics 进行了系统建模，弥补了以往对β-内酰胺酶抑制剂目标暴露水平研究的不足。研究通过群体药代动力学模型和蒙特卡洛模拟揭示了肾功能及CRRT流速对他唑巴坦清除的重要影响。结果指出在常规剂量下低浓度目标易达成，而高阈值目标在肾功能增强人群中不足，提示需个体化调整剂量或监测血药浓度。其创新在于首次定量描述CRRT条件下TAZ暴露与目标达成率的关系，但局限在样本量有限及模拟假设与临床实际可能存在差异。

---

## 8. 新生儿败血症治疗中磷霉素与氟氧头孢的药代动力学与安全性研究（NeoSep1 第一部分）

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41459929)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41459929
**DOI：** 10.1128/aac.01126-25

### 第一部分 原文与翻译

**英文原标题：** Pharmacokinetics and safety of fosfomycin and flomoxef administered as part of neonatal sepsis treatment (NeoSep1 Part 1).

> **英文摘要：**
> Neonatal doses for the off-patent antibiotics fosfomycin and flomoxef, which offer coverage against many extended-spectrum beta-lactamase (ESBL)-producing organisms, are based on limited data. We performed a pharmacokinetic (PK) and safety study of fosfomycin and flomoxef to confirm proposed neonatal dosing before further investigation in a trial (NeoSep1, ISRCTN48721236). Neonates with suspected sepsis, weighing more than 1,000 g, were sequentially enrolled into three antibiotic treatment cohorts: fosfomycin and amikacin (Cohort 1), flomoxef and amikacin (Cohort 2), and flomoxef and fosfomycin (Cohort 3), and followed for 28 days. Plasma samples were taken for PK assessment, with population PK modeling and simulations performed. Sixty-two neonates (48/62 [77%] preterm; 48/62 [77%] ≤7 days postnatal age [PNA]) received at least one dose of study antibiotics. Fosfomycin and flomoxef plasma concentrations were best described by a two-compartment and a one-compartment model, respectively, with postmenstrual age and PNA significantly influencing clearance. The probability of target attainment for fosfomycin was 100% for minimum inhibitory concentrations (MICs) of up to 8 mg/L, and for flomoxef, it was 100% for MICs of up to 0.5 mg/L. Adverse events (AEs) were common in this critically ill cohort. Thirteen (21%) neonates developed 19 trial antibiotic-related AEs (17 with grade ≤2, and 2 of grade 3), none of which required modification or discontinuation of allocated treatment. Seven neonates (11.6%) died. In this predominately preterm population, fosfomycin and flomoxef were safe, with drug exposures similar to published studies supporting the proposed doses for the larger, randomized NeoSep1 trial.This study is registered with ISRCTN48721236.

> **中文摘要：**
> 针对已过专利期的抗生素磷霉素和氟氧头孢的新生儿剂量，目前仅有有限数据可依据，而这两种药物能够覆盖多种产超广谱β-内酰胺酶（ESBL）的细菌。我们开展了一项磷霉素与氟氧头孢的药代动力学（PK）和安全性研究，以在后续临床试验（NeoSep1，ISRCTN48721236）前验证所建议的新生儿给药方案。纳入疑似败血症且体重超过1,000克的新生儿，按序分入三种抗生素治疗队列：磷霉素+阿米卡星（队列1）、氟氧头孢+阿米卡星（队列2）、氟氧头孢+磷霉素（队列3），并随访28天。采集血浆样本进行PK评估，同时开展群体药代模型与模拟分析。共有62名新生儿接受至少一次研究药物给药，其中48名（77%）为早产儿，48名（77%）出生后年龄≤7天。分析显示，磷霉素血浆浓度最符合双室模型，氟氧头孢最符合单室模型；胎龄及出生后年龄均显著影响清除率。磷霉素对最低抑菌浓度（MIC）≤8 mg/L的目标达成概率为100%，氟氧头孢对MIC≤0.5 mg/L亦为100%。该危重患儿队列中不良事件（AE）较常见，共13名（21%）新生儿出现19例与研究抗生素相关AE（17例为≤2级，2例为3级），均无需调整或停药处理。共有7名新生儿（11.6%）死亡。在以早产儿为主的人群中，磷霉素与氟氧头孢安全，药物暴露水平与已发表研究相似，支持其用于后续规模更大、随机化的NeoSep1试验。本研究已注册于ISRCTN48721236。

### 第二部分 AI 大师评价

该研究旨在明确磷霉素与氟氧头孢在新生儿败血症治疗中的药代动力学特征与安全性，为后续NeoSep1随机对照试验提供剂量依据。研究设计严谨，采用群体药代分析并结合临床队列观察，验证了两种药物在早产及新生儿人群中的安全暴露。结果显示两药在推荐剂量下均能实现充分的药效目标且耐受良好。该研究的创新在于系统填补了新生儿抗感染治疗领域的剂量证据空白，但样本量有限及分析时间较短可能限制其外推性。

---

## 9. 在发生心源性休克或心脏骤停后接受经皮冠状动脉介入治疗的危重患者中使用坎格雷洛：系统性综述与荟萃分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41457245)
**期刊：** Critical care (London, England)
**PMID：** 41457245
**DOI：** 10.1186/s13054-025-05812-x

### 第一部分 原文与翻译

**英文原标题：** Cangrelor in critically ill patients with cardiogenic shock or post-cardiac arrest undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本研究是一项系统性综述与荟萃分析，旨在评估坎格雷洛在伴有心源性休克或心脏骤停后需行经皮冠状动脉介入治疗的危重病人中的安全性与有效性。作者通过整合现有文献，尝试为此类高危患者的抗血小板治疗提供循证依据。研究的创新点在于聚焦罕见且高风险的危重组人群，填补了该领域的循证空白。然而，由于缺乏原始摘要，研究设计细节及结果解读仍需参考全文以获得更完整的学术理解。

---

## 10. 巨剂量抗坏血酸钠用于逆转革兰阴性菌脓毒症所致心血管、脑和肾功能障碍的剂量优化前临床随机对照研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41457243)
**期刊：** Critical care (London, England)
**PMID：** 41457243
**DOI：** 10.1186/s13054-025-05799-5

### 第一部分 原文与翻译

**英文原标题：** A preclinical randomised controlled dose optimization of megadose sodium ascorbate for reversal of gram-negative sepsis-induced cardiovascular, brain and kidney dysfunction.

> **英文摘要：**
> BACKGROUND: Megadose sodium ascorbate has shown promise as a treatment to reverse the pathophysiological effects of ovine Gram-negative sepsis. In human septic shock, lower doses of sodium ascorbate improved urine output and reduced vasopressor requirements compared with placebo. We sought to determine the minimum therapeutic dose of sodium ascorbate required to reverse sepsis-induced cardiovascular and renal dysfunction in sheep.
> 
> METHODS: Healthy young adult sheep were instrumented with renal artery flow probes, and oxygen-sensing and laser Doppler probes in the kidneys. Non-anaesthetised animals were infused with live Escherichia coli for 31-h. At 23.5-h of sepsis, four groups (n = 7-8/group) received fluid resuscitation (30 mL/kg Hartmann's solution) and were randomized to intravenous sodium ascorbate (1.0, 2.0, or 3.0 g/kg) or vehicle, delivered as a bolus followed by 7-h infusion. Norepinephrine was titrated to maintain mean arterial pressure (MAP) at ~ 70 mmHg.
> 
> RESULTS: At 23-h of sepsis, animals developed hypotension, hyperlactatemia, acute kidney injury, and renal medullary hypoxia. Vehicle-treated sheep required escalating doses of norepinephrine (from 0.4 to 0.8 ± 0.2 µg/kg/min) to restore MAP. Sodium ascorbate at 3.0 g/kg (achieving plasma ascorbate levels of ~ 10 mmol/L) rapidly restored MAP, allowing withdrawal of norepinephrine in half the animals (P = 0.007). Lower doses of sodium ascorbate (1.0 and 2.0 g/kg) had no significant effect on vasopressor requirements. The improvements in renal medullary oxygenation (25.2 ± 3.3 to 43.4 ± 4.5 mmHg, P = 0.04) and urine flow (from 0.5 ± 0.2 to 6.9 ± 2.4 ml/kg/h, P < 0.0001) were dose-dependent. Renal medullary tissue protein expression of nuclear factor kappa-light chain-enhancer B was significantly reduced with 3.0 g/kg of sodium ascorbate (to -52.9 ± 13.3%, P = 0.0005) and phosphorylated endothelial nitric oxide synthase at Ser-1177 was upregulated (to +219.5 ± 51.4%, P = 0.04) compared with vehicle-treated sheep.
> 
> CONCLUSIONS: In established ovine Gram-negative sepsis, only 3.0 g/kg sodium ascorbate effectively restored cardiovascular and renal dysfunction, which was associated with suppression of renal inflammatory signalling and restoration of endothelial nitric oxide activity. These findings demonstrate a clear dose-dependent therapeutic threshold, where achieving plasma ascorbate concentrations of ~ 10 mmol/L is essential to elicit multi-organ protection.

> **中文摘要：**
> 背景：巨剂量抗坏血酸钠已显示出逆转绵羊革兰阴性菌脓毒症病理生理效应的潜力。在人类脓毒性休克中，与安慰剂相比，较低剂量的抗坏血酸钠可改善尿量并减少血管加压药的需求。我们旨在确定逆转脓毒症导致的心血管和肾功能障碍所需的抗坏血酸钠最低治疗剂量。
> 
> 方法：健康成年绵羊植入肾动脉血流探头及肾脏氧传感和激光多普勒探头。未麻醉的动物接受连续31小时的活性大肠杆菌静脉输注。在脓毒症发作23.5小时时，将动物分为四组（每组n=7-8），接受补液复苏（Hartmann溶液30 mL/kg），并随机分配为静脉注射抗坏血酸钠（1.0、2.0或3.0 g/kg）或载体对照，以推注后紧接7小时持续输注的方式给药。通过滴定去甲肾上腺素维持平均动脉压（MAP）约为70 mmHg。
> 
> 结果：在脓毒症发作23小时后，动物出现低血压、高乳酸血症、急性肾损伤及肾髓质缺氧。接受载体处理的绵羊需要逐步增加去甲肾上腺素剂量（从0.4升至0.8 ± 0.2 µg/kg/min）以恢复MAP。3.0 g/kg抗坏血酸钠组（血浆抗坏血酸水平约达10 mmol/L）可迅速恢复MAP，使一半动物得以撤除去甲肾上腺素（P=0.007）。较低剂量（1.0和2.0 g/kg）对血管加压药需求无显著影响。肾髓质氧合（25.2 ± 3.3至43.4 ± 4.5 mmHg, P=0.04）及尿流量（0.5 ± 0.2至6.9 ± 2.4 mL/kg/h, P<0.0001）的改善呈剂量依赖性。与载体组相比，3.0 g/kg抗坏血酸钠显著降低了肾髓质组织核因子κB蛋白表达（下降52.9 ± 13.3%, P=0.0005），并上调了Ser-1177位点磷酸化的内皮型一氧化氮合酶（增加219.5 ± 51.4%, P=0.04）。
> 
> 结论：在既定的绵羊革兰阴性菌脓毒症模型中，仅3.0 g/kg抗坏血酸钠能有效恢复心血管与肾功能障碍，该效应与抑制肾脏炎症信号及恢复内皮一氧化氮活性相关。结果显示出明确的剂量依赖性治疗阈值，实现血浆抗坏血酸浓度约10 mmol/L是诱导多器官保护的关键。

### 第二部分 AI 大师评价

本研究通过随机对照前临床实验，明确评估了不同剂量抗坏血酸钠在脓毒症模型中的逆转效应。结果揭示，仅高剂量（3.0 g/kg）能有效改善心血管与肾功能，并展现显著的抗炎与内皮保护作用。研究在剂量-效应阈值方面提供了新见解，提示血浆抗坏血酸约10 mmol/L为多器官保护的关键水平。其创新之处在于首次系统探讨巨剂量抗坏血酸钠的最小有效剂量，但局限于动物模型，需进一步临床验证。

---

速递结束，祝您工作愉快！